Who are Akynzeo solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fosnetupitant/ palonosetron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/akynzeo-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Akynzeo solution — Competitive Intelligence Brief

Akynzeo solution (Akynzeo solution) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NK1 receptor antagonist / 5-HT3 receptor antagonist combination. Area: Oncology.

marketed NK1 receptor antagonist / 5-HT3 receptor antagonist combination NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Akynzeo solution (Akynzeo solution) — Helsinn Healthcare SA. Akynzeo is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) that prevents chemotherapy-induced nausea and vomiting by blocking two key pathways in the chemoreceptor trigger zone and gastrointestinal tract.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Akynzeo solution TARGET	Akynzeo solution	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
fosnetupitant/ palonosetron	fosnetupitant/ palonosetron	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (substance P receptor) / 5-HT3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NK1 receptor antagonist / 5-HT3 receptor antagonist combination class)

Helsinn Healthcare SA · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Akynzeo solution — Competitive Intelligence Brief. https://druglandscape.com/ci/akynzeo-solution. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab